1. Fang L, Kim MJ, Li Z, Wang Y, DiLiberti CE, Au J, et al. Model-informed drug development and review for generic products: summary of FDA Public Workshop. Clin Pharmacol Ther. 2018;104:27–30.
2. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, Califano A, et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH White Paper by the QSP Workshop. Group. 2011.
3. Lionberger R. Using quantitative methods and modeling to transform generic drug development and review.
https://www.fda.gov/downloads/Drugs/NewsEvents/UCM582148.pdf
. 2017. Accessed 31 Oct 2018.
4. USFDA. Guidance for industry: considering whether an FDA-regulated product involves the application of nanotechnology.
https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM401695.pdf
. 2014. Accessed 31 Oct 2018.
5. USFDA. Guidance for industry: drug products, including biological products, that contain nanomaterials.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM588857.pdf. 2017. Accessed 31 Oct 2018.